Kornimate/medical-research-clean huggingface dataset:
evaluation of the safety and performance of magneto microcatheter

Conditions: Ischemic Stroke

Summary: a prospective, open label single arm feasibility study to evaluate the safety and performance of the magneto microcatheter in patients diagnosed with acute ischemic stroke and planned for thrombectomy procedure.


Eligibility criteria:
inclusion criteria: 1. clinical signs consistent with acute ischemic stroke 2. patient with acute ischemic stroke within 24 hours from symptoms o 3. age 18-85 years old 4. consent process is completed per international and local regulations exclusion criteria: 1. known use of cocaine or other vasoactive substance 2. known bleeding diathesis 3. any known hemorrhagic or coagulation deficiency. 4. current use of oral anticoagulants with international normalized ratio (inr) \> 3; 5. ptt (partial thromboplastin time)\>2 at screening 6. uncontrolled hypertension (systolic blood pressure\>185 or diastolic blood pressure\>110) refractory to pharmacological management 7. pregnant or lactating female 8. ct scan or mri with evidence of acute intracranial hemorrhage, aspect score\<6, mass effect and/or intracranial tumor 9. angiographic evidence of either carotid dissection or vasculitis at the target site or any condition that may limit device access to the target site (i.e high grade stenosis) per the treating physician's discretion.
internet-based multidisciplinary rehabilitation for longterm covid-19 syndrome

Conditions: Long COVID-19

Summary: internet-based multidisciplinary interventions will be offered to participants suffering from longterm covid-19 syndrome. data will be collected by internet platform at karolinska institutet (bass) before, after rehabilitation and at follow-up after 6 months. both self-scored questionnaires and physical tests performed at home will be collected to understand the symptomatology, functioning and activity level. rehabilitation during 8 weeks period will be given in groups as face-to-group, pre-recorded film sessions and by individual approach, the participants will use exorlive app for physical activity.

this randomised study aimed to understand if multidisciplinary internet-based interventions performed in group and individually are applicable for participants suffering from longterm covid-19 syndrome. data will be collected by internet platform at karolinska institutet (bass) before, after rehabilitation and at follow-up after 6 months. both self-scored questionnaires and physical tests performed at home will be collected to understand the symptomatology, functioning and activity level. rehabilitation during 8 weeks period will be given in groups as face-to-group, pre-recorded film sessions and by individual approach, the participants will use exorlive app for physical activity. the participants will be randomised for treatment and waiting lists using a website random.org. waiting list will be offered rehabilitation interventions after at least 8 weeks period of waiting to exclude a spontaneous improvement or worsening of symptoms. to understand the impact of rehabilitation on work capacity and employment/economic supply, the data from social insurance databas will be obtained 2021 year before and upp to 2 years after the intervention. to understand the impact of rehabilitation on sickness-leave, the data from national insurance agency will be obtained for 2021 and 2022.

Eligibility criteria:
inclusion criteria: * confirmed covid-19 infection * post-infection symptoms lasting longer than 3-6 months * clinically stable persons regarding symtoms or other co-morbidities * ability to participate in internet-based rehabilitation in group in swedish. exclusion criteria: * uncertainty regarding covid-19 infection or co-morbidities started or exacerbated during the same time * alcohol and drug abuse * untreated psychiatric and somatic co-morbidities * undergoing medical or psychotherapeutic treatment or rehabilitation which can interact with rehabilitation outcomes.

Keywords: covid-19 rehabilitation telemedicine multidisciplinary
use of 3,4-diaminopyridine (3,4-dap) in the treatment of lambert eaton myasthenic syndrome

Conditions: Lambert-Eaton Myasthenic Syndrome

Summary: compassionate use of orphan drug 3,4-diaminopyridine(dap) in treatment of lambert eaton myasthenic syndrome (lems). 3,4-dap is used to decrease the muscle weakness associated with lems and hopefully will decrease the need for prednisone and all other therapies that were previously required to control symptoms. how long a patient will take 3,4 dap depends upon if he/she is seeing benefits from the medication or experiencing side effects that will prevent them from continuation in the study.

3,4-diaminopyridine (3,4-dap) decreases symptoms of weakness in patients with lems, and therefore can be used to decrease the amount of immune modulation therapy needed to provide an equivalent degree of disease control.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of lems with or without any of the following: evidence of underlying malignancy, presence of p/q or n-type calcium channel antibodies, electrodiagnostic evidence of a presynaptic defect of neuromuscular junction transmission.none of these laboratory findings are required for inclusion in this study. 2. p/q and n type calcium channel antibodies are measured in the blood as a routine laboratory test during the course of initial diagnosis, but 10-20% of patients with lems do not have elevated levels of these antibodies. exclusion criteria: 1. hypersensitivity to any component of this medication. 2. history of past or current seizures. 3. history of asthma. 4. evidence of prolonged qt syndrome. there is no absolute upper limit of normal for the qtc interval. 5. family history of prolonged qtc syndrome, history of unexplained syncope, seizures or cardiac arrest.
mindfulness intervention for post-covid symptoms

Conditions: COVID-19; Post Acute Sequelae of SARS-CoV-2

Summary: the purpose of this study is to assess the feasibility of using a wearable brain-sensing wellness device (muse-s) to potentially reduce stress and anxiety during post-covid, which is characterized by increased stress and anxiety.

this study will answer the following questions: 1) will patients experiencing long-covid syndrome utilize a wearable brain-sensing wellness device to potentially reduce stress and anxiety 2) does using this wearable brain-sensing wellness device help decrease stress and anxiety in patients who are experiencing long-covid syndrome.

Eligibility criteria:
inclusion criteria: * identified with one of 3 post-covid syndrome (pasc) phenotypes at mayo clinic rochester. * not pregnant by subject self-report at time of consent. * have the ability to provide informed consent. * have the ability to complete all aspects of this trial. * have access to an iphone, ipad, or android device. * have no contraindicating comorbid health condition which would interfere with the proper use of the muse-sô system, as determined by the clinical investigators. exclusion criteria: * used an investigational drug within the past 30 days. * anyone that is not on a stable dose of medication for anxiety, depression or sleep. * currently (within the past 3 weeks) been practicing mindfulness training on a weekly/regular basis. * currently (within 3 weeks) has been enrolled in another clinical or research program which intervenes on the patients' qol, or stress. * an unstable medical or mental health condition as determined by the physician investigator.

Keywords: covid-19 pasc pandemic meditation
outcomes of subthreshold laser versus intravitreal injection of ranibizumab in diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: the aim of this study is to compare the anatomical and functional results of intravitreal( iv) injection of ranibizumab with sub threshold micropulse laser ( sml) in treatment of diabetic macular edema (dme) both anatomically by spectral domain optical coherence tomography (sd oct) and functionally by best-corrected visual acuity (bcva) and multifocal electroretinogram (mferg).

diabetic macular edema (dme) causes significant visual loss in diabetic patients. about 20% and 40% of patients with type 1 and type 2 diabetes mellitus (dm), respectively, develop dme. one-third of diabetic patients who have had dm for more than twenty years will develop dme . early impairment in the function of the middle and inner layers of the retina has been reported in diabetic patients before appearance of vascular complications . a good independent guide of macular function in patients with dme is multifocal electroretinogram (mferg) readings from the macular area, which strongly associate with morphologic alterations in the macula. some investigators suggested that temporal characteristic (implicit time) of mferg waves are more important than amplitudes for evaluation of retinal function in diabetic patients. they concluded that patients with dm show temporal changes indicating delayed neural transmission due to local impairment of blood glucose metabolism. in contrast, others emphasize the importance of both parameters (implicit time and amplitude) in identifying retinal affection in dm. intravitreal (iv) injections of anti-vascular endothelial growth factor (vegf) agents provided good visual outcomes in treatment of dme. however, iv anti-vegf injections are expensive, need to be repeated many times and have the potential risk of causing endophthalmitis . subthreshold micropulse laser (sml) treatment of dme has the same effect as conventional laser treatment, nonetheless, there is less damage to adjacent tissues of the burn area in the retinal pigment epithelium (rpe). sml allows laser emission to be divided into bursts of short cyclic pulses that remain for microseconds permitting substantial cooling amid these short pulses .

Eligibility criteria:
inclusion criteria: * dme with bcva\<0.5 decimal snellen acuity. * controlled blood glucose (hba1c) \<6.5%. exclusion criteria: * history of previous intraocular surgery, * history of previous laser treatment, * history of previous iv injection, * macular disease or ischemia, * proliferative diabetic retinopathy, * vitreoretinal traction, * interruption of external limiting membrane (elm) or ellipsoid zone (ez). * dense media opacity, * optic disc pathology * history of strokes or ischaemic heart diseases. * patients with (cst) \> 400 µm on oct .

Keywords: dme, mferg, sml, ranibizumab,iv.injection
vascular remodeling and the effects of angiogenic inhibition in diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: the retinal vasculature changes dramatically in patients with diabetic retinopathy especially between non-proliferative and proliferative disease. the retinal vasculature can be imaged and quantified using special dyes. this study will test whether the pattern of the retinal vasculature changes in patients with different levels of diabetic retinopathy can be quantified using computerized image analysis. in addition, the study will evaluate whether new drugs to treat diabetic retinopathy will be able to reverse these vascular changes.

in this study, we are studying whether vascular density decreases during diabetic retinopathy prior to the pathological neovascularization seen in proliferative disease that results in blindness in more than 50 percent of patients, and whether the adverse, early vascular remodeling and neovascularization can be reversed by anti-angiogenic therapeutics. we have shown that vascular density decreases during early stages of diabetic retinopathy, prior to the pathological neovascularization that defines proliferative retinopathy, and that this change may be reversible with new anti-angiogenic therapeutics. to test this hypothesis we will determine (1) how blood vessels remodel and whether vascular density truly decreases during diabetic retinopathy and (2) how the anti-angiogenic steroid triamcinolone acetonide affects vascular density and pattern during human diabetic retinopathy and in our experimental model, the avian cam model. twenty patients (n = 20) for each of the 4 npdr stages will be enrolled. in addition, a control group of 20 normal subjects will be recruited from the same clinical practice that do not have diabetes and no evidence of any vascular disease, for a total of 100 patients in the clinical trial.

Eligibility criteria:
inclusion criteria: - presence of mild, moderate, severe, or very severe non-proliferative diabetic retinopathy (defined as etdrs level \>10) in at least one eye (based on etdrs criteria) exclusion criteria: * any condition that might impair the patient's ability to give informed consent * any condition or media opacity that might impair the patient's ability to perform vision tests, color fundus photographs or fluorescein angiography * severe allergy or other contraindication to sodium fluorescein dye * participating in any other ophthalmic clinical trial

Keywords: diabetic retinopathy fluorescein angiography steroid anti-angiogenesis
ezrin peptide (hep-1) for treatment of coronavirus disease (covid-19) infection

Conditions: Covid19; Treatment; Corona Virus Infection

Summary: currently, sars-cov-2 the novel member of the corona virus family, affecting the world leading to covid-19 disease. it can result life-threatening condition by developing severe acute respiratory distress syndrome (ards). based on previous evidence a group of patients with severe covid-19 develop a cytokine storm syndrome which leads to hyper-inflammation lung tissue damage. supportive care is the current management of covid-19 is and management of ards as a main cause of mortality has been remained challenging. therefore, an urgent effective treatment of covid-19 regarding hyper-inflammation mechanism is required. currently, development of novel anti-viral agents and vaccines are the main issues. however, it needs long time, from months to years, until suitable new medications and vaccines have been developed. an immune-modulatory tetra deca peptide (14-mer peptide) named human ezrin peptide 1 (hep-1) (trade name gepon) was introduced by the group of ataullakhanov in russia. regarding its proved anti-viral and anti-inflammatory effect, russian authorities approved gepon for treatment of ulcerative colitis treatment and hepatitis -c. in this regard, it seems that hep-1 is a very safe immune-modulatory agent which can be effective in the management of covid-19 infection without any adverse effect for the patient.


Eligibility criteria:
inclusion criteria: * patients hospitalized with a positive sars-cov-2 pcr test and presenting with one or more clear clinical symptoms of covid-19 disease * no contraindication to hep-1 * obtained informed consent exclusion criteria: * patients who had received any immuno-modulator therapy * active or chronic kidney/ liver diseases, * oncological diseases * other viral infection including hiv and hepatitis. * any allergic reaction or sensitivity to hep-1 * breast feeding or pregnancy

Keywords: covid19 treatment ezrin peptide hep-1
effects of peppermint oil in cardiometabolic outcomes

Conditions: Cardiometabolic Syndrome

Summary: cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. previous non-randomized interventions have shown that oral peppermint may be beneficial in improving cardiometabolic outcomes. however, to date, no research has explored this using a placebo randomized intervention. therefore, the primary purpose of the proposed investigation is to test the ability of oral peppermint oil supplementation to improve cardiometabolic parameters in healthy individuals.


Eligibility criteria:
inclusion criteria: * healthy * between 18 \& 65 years * non-smoker * bmi \< 30 * able to give informed consent exclusion criteria: * pregnancy * diabetes or any other metabolic/ uncontrolled hypertensive conditions * food allergies to peppermint * habitual consumption of peppermint * not regularly taking medication or antioxidant supplements
effect sildenafil and estradiiol valerate on endometrial thickness in infertile women

Conditions: Endometrial Thickness

Summary: the endometrium is a dynamic tissue that responds to changing hormonal signals throughout the cycle. the changes in the endometrial composition are expressed in alteration in gene expression, micro architectural morphological changes as well as in protein and hormone secretion. these factors combine together to construct the "window of implantation" a short period of time during the luteal phase in which the endometrium is receptive. thin endometrium is associated with a low pregnancy rate. endometrial thickness 7 mm in the pre-ovulatory phase is widely accepted to be cut-off of thin endometrium. for that the aim of this study is to compare the effect of sildenafil-estrogen combination to estrogen alone on endometrium thickness in infertile women. half of the patients will receive estrogen ( estradiol valerate ) and the other half will receive combination of sildenafil-estrogen .

being a hormone dependent tissue, the endometrium proliferates in response to estrogen, which further induces the production of progesterone receptors. as a result, infertile patients who demonstrated thin endometrium, were offered estradiol (e2) remedies, in an attempt to improve endometrial proliferation. most of the studies regarding e2 treatment in patients with thin endometrium dealt with frozen-thawed embryo transfer cycles. moreover, while there are several routes and duration of administration of e2, including per os, transdermal, intramuscular and vaginal, no compelling advantage for one protocol for endometrial preparation over another, with regard to pregnancy rates, has been established. sildenafil acts as a type 5-specific phosphodiesterase inhibitor hence augments the vasodilatory effects of nitric oxide by preventing the degradation of cgmp. nitric oxide (no) relaxes vascular smooth muscle through a cgmp-mediated pathway and no synthase isoforms have been identified in the uterus. a decade ago, sher and fisch studied the effect of vaginal sildenafil on the endometrial thickness of infertile patients with poor endometrial development, who underwent ivf treatment. they have demonstrated improved uterine artery blood flow and endometrial growth, with higher implantation and ongoing pregnancy rates following vaginal sildenafil administration.

Eligibility criteria:
inclusion criteria: 1. patients having ovulatory infertility. 2. age: 20-35 years old. 3. bmi less than 30 kg/m2 exclusion criteria: 1. women who have any congenital uterine anomaly (e.g., unicornuate uterus or infantile uterus) or acquired deformities of the uterine cavity that interfere with embryo implantation (as asherman syndrome). 2. women who have any tubal factor that relates to infertility (e.g., tubal adhesion or previous ectopic pregnancy). 3. women who have contraindication for estrogen treatment (e.g., history of stroke, dvt and benign liver disease). 4. women who have male factor for infertility (e.g., azoospermia, teratospermia).
fidgety movements of preterm neonates included in cosgod iii

Conditions: Preterm; General Movements; Fidgety Movements; Near Infrared Spectroscopy; Neurological Outcome

Summary: the evidence on the effects of clinical care with cerebral nirs (near-infrared spectroscopy) monitoring on short term neurological outcome, displayed by fidgety movements between six to 20 weeks post term, are still uncertain. two centers (graz and innsbruck), who participated in the cosgod iii trial, routinely performed gma between 37+0 to 42+0 weeks of corrected age (writhing movements) and between six to 20 weeks post term (fidgety movements). aim of the present study is therefore to assess in neonates, who were included into the cosgod iii trial, in a retrospective observational study routinely performed fidgety movements between six to 20 weeks of corrected age after discharge. the investigators hypothesise that the preterm neonates in the intervention group of the cosgod iii trial show better survival and short term neurological outcome, displayed by normal fidgety movements, compared to neonates in the control group.


Eligibility criteria:
inclusion criteria: * preterm neonates included in the cosgod iii trial * death * routinely performed fidgety movement (fm) analysis between six to 20 weeks post term exclusion criteria: * neonates without fm analysis between six to 20 weeks post term

Keywords: near-infrared spectroscopy preterm neonates preterm birth cerebral injury cerebral oxygenation resuscitation neurological outcome fidgety movements general movements
evaluating whether integration of prognostic and predictive algorithms into routine clinical practice effect whether oncologists order multigene assays in patients with early stage breast cancer

Conditions: Breast Cancer

Summary: a broad range of prognostic and predictive tools are available for patients with newly diagnosed early stage breast cancer. these range from free and publicly available mathematical algorithms, through to expensive genomic tests. it is not known how the use of these different scores affects physician decision making with respect to ordering genomic tests, nor how well these algorithms predict for the results of oncotype dx ® in the real-world setting. this pragmatic study will help to answer these questions.

a broad range of prognostic and predictive tools are available for patients with newly diagnosed early stage hormone receptor positive, her2 negative breast cancer. these range from free and publicly available mathematical algorithms (e.g. nhs predict, magee formulae, gage and tennessee equations) that incorporate standard pathology results, through to expensive genomic tests (e.g. oncotype dx ® and endopredict ®). it is not known how the use of these different scores affects physician decision making with respect to ordering genomic tests, nor how well these algorithms predict for the results of oncotype dx ® in the real-world setting. this pragmatic study will help to answer these questions. in summary: month 1 to 3: pathology and chemotherapy data is collected, no physician questionnaires given. month 4 to 6: pathology and chemotherapy data collected, plus physician questionnaire administered. intervention teaching after 6 months of study activation. month 7 to 9: pathology and chemotherapy data collected, predict 2.1 tool used, no physician questionnaire given. month 10 to 12: pathology and chemotherapy data collected, predict 2.1 tool used, plus physician questionnaire administered.

Eligibility criteria:
inclusion criteria: * histologically confirmed primary breast cancer * no prior chemotherapy * eligible for oncotype dx ® testing as per current ontario funding criteria including: er positive, pr positive or negative, her2 negative, lymph node status negative or micro-invasive disease, tumor \>1 cm in size (or if equal or \<1 cm, must be grade 2/3 or have lymph node micrometastasis). exclusion criteria: * neoadjuvant treatment including window of opportunity trials * recurrent breast cancer

Keywords: predict 2.1 oncotype dx